Identification of ANKRD13D as a potential target in renal cell carcinomas.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-06-01 Epub Date: 2024-03-06 DOI:10.1177/03936155241236498

Wenqian Zhou, Yonghe Huang, Jing Liu, Yiguo Liu, Yuqing Liu, Chen Yu

{"title":"Identification of ANKRD13D as a potential target in renal cell carcinomas.","authors":"Wenqian Zhou, Yonghe Huang, Jing Liu, Yiguo Liu, Yuqing Liu, Chen Yu","doi":"10.1177/03936155241236498","DOIUrl":null,"url":null,"abstract":"Background: The correlation of the expression of ankyrin repeat domain (ANKRD) family members with renal cell carcinoma prognosis was investigated.Methods: The GEPIA2, GEO2R, UALCAN, GDC, OncoLnc, TIMER, PanglaoDB, CancerSEA, and Tabula Muris databases were used. Twelve ANKRD family members were identified as having overexpressed renal cell carcinoma samples. The ANKRD13D was identified as a renal cell carcinoma-specific target by cross-referencing the multiple survival databases. To clarify the role of ANKRD13D, the expression of NAKRD13D was analyzed at the single-cell level.Results: ANKRD13D was mainly expressed in immune cells and positively correlated with Treg cell infiltration. The expression of ANKRD13D was also positively correlated with PDCD1, CTLA4, LAG3, TNFSF14, and ISG20. The overexpression of ANKRD13D in Treg was confirmed using reverse transcription-quantitative polymerase chain reaction. The structure of ANKRD13D was predicted using AlphaFold.Conclusion: In conclusion, we identified ANKRD13D as a key immune regulator, and targeting ANKRD13D with immune checkpoints blockade may be a promoting strategy for renal cell carcinoma immunotherapy.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03936155241236498","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The correlation of the expression of ankyrin repeat domain (ANKRD) family members with renal cell carcinoma prognosis was investigated.

Methods: The GEPIA2, GEO2R, UALCAN, GDC, OncoLnc, TIMER, PanglaoDB, CancerSEA, and Tabula Muris databases were used. Twelve ANKRD family members were identified as having overexpressed renal cell carcinoma samples. The ANKRD13D was identified as a renal cell carcinoma-specific target by cross-referencing the multiple survival databases. To clarify the role of ANKRD13D, the expression of NAKRD13D was analyzed at the single-cell level.

Results: ANKRD13D was mainly expressed in immune cells and positively correlated with Treg cell infiltration. The expression of ANKRD13D was also positively correlated with PDCD1, CTLA4, LAG3, TNFSF14, and ISG20. The overexpression of ANKRD13D in Treg was confirmed using reverse transcription-quantitative polymerase chain reaction. The structure of ANKRD13D was predicted using AlphaFold.

Conclusion: In conclusion, we identified ANKRD13D as a key immune regulator, and targeting ANKRD13D with immune checkpoints blockade may be a promoting strategy for renal cell carcinoma immunotherapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

将 ANKRD13D 鉴定为肾细胞癌的潜在靶点。

背景：研究了ankrin重复域（ANKRD）家族成员的表达与肾细胞癌预后的相关性：研究了ankrin重复结构域（ANKRD）家族成员的表达与肾细胞癌预后的相关性：方法：使用GEPIA2、GEO2R、UALCAN、GDC、OncoLnc、TIMER、PanglaoDB、CancerSEA和Tabula Muris数据库。结果发现12个ANKRD家族成员在肾细胞癌样本中有过表达。通过交叉比对多个生存数据库，发现ANKRD13D是肾细胞癌的特异性靶点。为了明确ANKRD13D的作用，在单细胞水平上分析了NAKRD13D的表达：结果：ANKRD13D主要在免疫细胞中表达，并与Treg细胞浸润呈正相关。ANKRD13D的表达还与PDCD1、CTLA4、LAG3、TNFSF14和ISG20呈正相关。反转录-定量聚合酶链反应证实了 ANKRD13D 在 Treg 中的过表达。使用 AlphaFold 预测了 ANKRD13D 的结构：总之，我们发现ANKRD13D是一种关键的免疫调节因子，用免疫检查点阻断剂靶向ANKRD13D可能是一种促进肾细胞癌免疫治疗的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊